The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select ...
KFA-115, also known as NVP-KFA115, is an immunomodulatory agent being developed by Novartis for the treatment of select advanced cancers.
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers.
People also ask
What is the mechanism of action of HIF2a inhibitors?
What is the mechanism of action for Anakinra?
What is the mechanism of action of Tezepelumab?
What is the mechanism of action of Darbepoetin Alfa injection?
The different mechanisms of action of anti-PD-1/anti-PD-L1 and anti-CTLA-4 antibodies resulted in clinical studies investigating combination therapies in ...
Nov 3, 2021 · The company uses a mechanism of action that is target-class agnostic and, it says, differentiated from other targeted protein degradation ...
Nov 19, 2024 · KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or the programmed ...
Missing: KFA115 | Show results with:KFA115
This study is a FIH, open-label, phase I, multi-center study that consists of two treatment arms in dose escalation: single-agent KFA115 (Arm A escalation) and ...
Missing: mechanism action
Jan 30, 2023 · This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of ...
The adenomatous polyposis coli (APC) gene, a tumor suppressor, plays a pivotal role in regulating the WNT/β-catenin signaling pathway. One of the key actions of ...
